MedscapeBiologics Projected to Transform Uveitis TreatmentMedscapeThese include the anti-CD20 inhibitors rituximab and ocrelizumab, the anti-TNF inhibitors certolizumab and golimumab, the interleukin-6 inhibitor tocilizumab, the interleukin-1 inhibitor…
Drug Discovery & Development |
Cancer drug Treanda gets orphan status, but that won’t save Teva’s shrinking …
FiercePharma The orphan tag applies to use of Treanda for indolent B-cell non-Hodgkin lymphoma (iNHL) that has progressed during or within 6 months of treatment with rituximab or a regimen containing rituximab. Orphan status is granted to therapies intended to … Teva Gets Additional Exclusivity for TreandaDrug Discovery & Development Teva Pharmaceutical Industries Limited : Teva Announces Additional Regulatory …4-traders (press release) Teva gains additional regulatory exclusivity for TreandaThe Pharma Letter |
Drug Discovery & Development |
Teva Gets Additional Exclusivity for Treanda
Drug Discovery & Development … Administration (FDA) has granted orphan drug exclusivity for Treanda through October 2015 for indolent B-cell non-Hodgkin lymphoma (iNHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. FDA grants Teva’s Treanda orphan drug statusGlobes Cancer drug Treanda gets orphan status, but that won’t save Teva’s shrinking …FiercePharma Teva Pharmaceutical Industries Limited : Teva Announces Additional Regulatory …4-traders (press release) |
Drug Discovery & Development |
FDA grants Teva’s Treanda orphan drug status
Globes … that the US Food and Drug Administration (FDA) has granted orphan drug exclusivity for Treanda through October 2015 for the treatment of indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with … Teva Pharmaceutical Industries Limited : Teva Announces Additional Regulatory …4-traders (press release) Teva Pharma Reports Addl. Regulatory Exclusivity For TREANDA For InjectionNASDAQ |
Teva Pharmaceutical Industries Limited : Teva Announces Additional Regulatory …4-traders (press release)TREANDA is indicated for the treatment of patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months…
Drug Discovery & Development |
Teva Announces Additional Regulatory Exclusivity for TREANDA …
Business Wire (press release) TREANDA is indicated for the treatment of patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Important Safety Information. FDA grants Teva’s Treanda orphan drug statusGlobes Teva Gets Additional Exclusivity for TreandaDrug Discovery & Development Cancer drug Treanda gets orphan status, but that won’t save Teva’s shrinking …FiercePharma |
|
Bendamustina più Rituximab contro il Linfoma non-Hodgkin
informazione.it (Comunicati Stampa) Roma, 26/11/2013 (informazione.it – comunicati stampa) I risultati di uno studio, pubblicato su “The Lancet”, dimostrano che l’associazione bendamustina più rituximab in pazienti con linfoma non-Hodgkin, indolente e mantellare, raddoppia la … |
|
Let’s Scale-Up Reduction of Childhood Cancer Burden
AllAfrica.com The child had been put on Rituximab (Mabthera). He was required to receive 6 doses, of Mabthera. Each dose would cost GH¢6,000.00. The problem was that the parents could not afford it and they were wondering if the Cancer Society of Ghana could assist … |
|
Rituximab : dépister une hépatite B avant d’initier le traitement
Doctissimo Les autorités de santé et le laboratoire Roche ont envoyé une lettre aux professionnels de santé concernés pour les informer sur les nouvelles recommandations relatives au risque de réactivation du virus de l’hépatite B chez les patients traités par … |
MedscapeASH 2013: Big Year for CLL, LymphomaMedscapeThe long-term follow-up of the PRIMA trial, which was R-chemotherapy followed by 2 years of rituximab maintenance or observation, showed a progression-free survival advantage but not an overall surviv…